HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- ((3- (3- 9H- purin- 6- yl)pyridin- 2- ylamino)- 2,4- difluorophenyl)furan- 3- sulfonamide

a B-Raf inhibitor; structure in first source

Also Known As:

UA1-201; UI-152

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - N-((3-(3-9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)furan-3-sulfonamide: 3
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - N-((3-(3-9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)furan-3-sulfonamide: 3
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - N-((3-(3-9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)furan-3-sulfonamide: 3

Experts

1.	Lee, Michael: 3 articles (03/2013 - 01/2012)
2.	Ahn, Jun-Ho: 2 articles (03/2013 - 01/2012)
3.	Ahn, Soon Kil: 2 articles (07/2012 - 01/2012)
4.	Kim, Yun-Ki: 1 article (07/2012)

Related Diseases

1.	Neoplasms (Cancer) 01/13/2012 - "In this study, we examined whether B-Raf inhibition by UI-152 may be an effective therapeutic strategy for eliminating cancer cells transformed with v-Ha-ras (Ras-NIH 3T3). " 07/28/2012 - "In cellular assays, UI-152 displayed high selectivity for tumor cells bearing B-Raf(V600E), showing more than 1000-fold higher inhibition of their proliferation than wild-type B-Raf-bearing cells. "
2.	Melanoma (Melanoma, Malignant) 07/28/2012 - "In the present study, the antiproliferative effect of the new oncogenic B-Raf targeting drug UI-152 on two types of melanoma cell lines with differing B-Raf mutational status was examined, and the underlying mechanisms were investigated. " 03/01/2013 - "To better understand the mechanisms that determine the long-term responses of mutant B-Raf melanoma cells to B-Raf inhibitor, we used chronic selection to establish B-Raf (V600E) melanoma clones with acquired resistance to the new oncogenic B-Raf inhibitor UI-152. " 07/28/2012 - "Collectively, our data suggest that UI-152 may be an effective B-Raf inhibitor and a potential therapeutic strategy for B-Raf(WT) and Ras mutant melanoma." 07/28/2012 - "Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152."

Related Drugs and Biologics

1.	Proto-Oncogene Proteins B-raf